Nolato AB (publ) (NLTBF) Q2 2026 Earnings Call Transcript

Thank you, and welcome to the presentation of the second quarter for Nolato Group. Starting on Page 2. We saw a quarter with growth in both business areas with a total growth of 4% currency adjusted with the strongest growth in the Medical business area. This was achieved in a difficult environment, I would say. So sales ended up at -- close to SEK 2.5 billion in the quarter, and that was then 4% adjusted currency growth. The profit EBITA ended up at SEK 247 million, creating a margin of 10.1%. The margin was affected by increased raw material prices and some start-up costs for new programs. Strong cash flow in the quarter ended up at SEK 287 million and as a total, we have a very strong financial position, enabling us to deliver on the intensified acquisition strategy as communicated previously. Turning to Page 3, summing up the group. So Nolato consists of 2 business areas that create synergies across. And both business areas are then working as a development and production partner for leading global customers. On Page 4, we see a summary of Medical Solutions' development